89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer

MLA

Epi Kanker Team C, et al. 89Zr-Pembrolizumab Imaging as a Non-Invasive Approach to Assess Clinical Response to PD-1 Blockade in Cancer. 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1432117891&authtype=sso&custid=ns315887.

APA

Epi Kanker Team C, Cancer, JC onderzoeksprogramma Cancer, Kok, I. C., Hooiveld, J. S., van de Donk, P. P., Giesen, D., van der Veen, E. L., Lub-de Hooge, M. N., Brouwers, A. H., Hiltermann, T. J. N., van der Wekken, A. J., Hijmering-Kappelle, L. B. M., Timens, W., Elias, S. G., Hospers, G. A. P., Groen, H. J. M., Uyterlinde, W., van der Hiel, B., … de Vries, E. G. E. (2022). 89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer.

Chicago

Epi Kanker Team C, Cancer, JC onderzoeksprogramma Cancer, I C Kok, J S Hooiveld, P P van de Donk, D Giesen, et al. 2022. “89Zr-Pembrolizumab Imaging as a Non-Invasive Approach to Assess Clinical Response to PD-1 Blockade in Cancer.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1432117891&authtype=sso&custid=ns315887.